Chaturvedi Pravin R 4
4 · Jaguar Health, Inc. · Filed Jun 26, 2025
Insider Transaction Report
Form 4
Chaturvedi Pravin R
Chief Scientific Officer
Transactions
- Award
Convertible Promissory Note
2025-06-24$20000.00/sh+3,785$75,700,000→ 3,785 totalExercise: $5.55→ Common Stock (3,785 underlying) - Disposition to Issuer
Convertible Promissory Note
2025-06-24$20000.00/sh−3,600$72,000,000→ 0 totalExercise: $5.55→ Common Stock (3,600 underlying) - Award
Warrant to Purchase Common Stock
2025-06-24+7,304→ 3,600 totalExercise: $2.70Exp: 2026-12-24→ Common Stock (7,304 underlying)
Footnotes (2)
- [F1]The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.
- [F2]As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 7,304 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.